



Patient Information	Specimen Information	Client Information
DOB: Gender: Patient ID: Health ID:	Specimen: Collected: Received: Reported:	Client #:

ColoVantage® (methylated Septin 9)

Lab: AMD

RESULT:

NEGATIVE: METHYLATED SEPTIN 9 NOT DETECTED

INTERPRETATION:

The negative methylated Septin 9 result indicates a reduced likelihood of colorectal cancer.

REVIEWER:

Masamichi Ito, Ph.D., FACMG Director, Molecular Genetics

SUPPLEMENTAL INFORMATION

Methylated Septin 9 is a DNA marker associated with colorectal cancer. In our validation studies, the clinical sensitivity of this marker was 70% and clinical specificity was 89%. This result should be interpreted in context of a clinical evaluation.

Methylated Septin 9 DNA in plasma is detected by Real-Time PCR.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute, Chantilly, VA. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

AMD QUEST DIAGNOSTICS/NICHOLS CHANTILLY, 14225 NEWBROOK DRIVE, CHANTILLY, VA 20151-2228 Laboratory Director: PATRICK W. MASON,MD,PHD, CLIA: 49D0221801
AT QUEST DIAGNOSTICS-ATLANTA, 1777 MONTREAL CIRCLE, TUCKER, GA 30084-6802 Laboratory Director: ANDREW N YOUNG,MD,PHD, CLIA: 11D0255931

CLIENT SERVICES: 866.697.8378

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics.